London Research & Pharmaceuticals presents the advancement of LRP-661, their oral cannabidiol sulphate drug candidate at the prestigious Epilepsy Therapies & Diagnostics Development (ETDD) XVII conference in Miami
LONDON, Ontario, April 15, 2024 (GLOBE NEWSWIRE) -- London Research & Pharmaceuticals has recently publicized data about its lead compound LRP-661 or Cannabidiol sulphate (CBDS), highlighting its safety, efficacy, bioavailability, and predictable PK parameters.
- LONDON, Ontario, April 15, 2024 (GLOBE NEWSWIRE) -- London Research & Pharmaceuticals has recently publicized data about its lead compound LRP-661 or Cannabidiol sulphate (CBDS), highlighting its safety, efficacy, bioavailability, and predictable PK parameters.
- CBDS maintains improved oral formulation capabilities vs cannabidiol, including tablet and water-based solutions.
- This data was presented at the prestigious ETDD XVII conference in Miami on June 2nd, 2023, and was well received by the expert audience.
- Following their presentation at ETDD XVII, London Research & Pharmaceuticals accepted a podium presentation invitation from Dr. Meir Bialer at the EILAT XVII held in Madrid, May 2024.